Skip to search formSkip to main contentSkip to account menu

otlertuzumab

A recombinant single-chain polypeptide engineered to exhibit the full binding and activity of an anti-CD37 monoclonal antibody with potential… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

TRU 016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
Otlertuzumab (TRU‐016) is a humanized anti‐CD37 protein therapeutic that triggers direct caspase‐independent apoptosis of… 
Review
2015
Review
2015
Emerging immunological drugs for chronic lymphocytic leukemia
Introduction: Over the last few years, several new immunological drugs, particularly monoclonal antibodies (mAbs… 
Review
2014
Review
2014
Anti-CD37 antibodies for chronic lymphocytic leukemia
Introduction: Immunotherapy using mAbs is a safe and effective method for the treatment of chronic lymphocytic leukemia (CLL) and… 
2014
2014
Phase 1b Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia (CLL)
Background: CD37 is a tetraspanin protein expressed on the surface of normal and transformed B cells across a wide range of… 
2014
2014
Otlertuzumab more than a TRU(E) toddler in CLL?
In this issue of Blood , Byrd et al present first-in-man data in chronic lymphocytic leukemia (CLL) using otlertuzumab (TRU-016… 
2014
2014
Evaluation of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Therapeutic in Preclinical Combination Studies with Kinase Inhibitors and a Next Generation Anti-CD20 Mab in Vitro and in Animal Models of…
Background: CD37 is a 50-55 kDa heavily glycosylated member of the tetraspanin superfamily of molecules. This cell surface… 
2014
2014
A phase 1 study evaluating the safety and tolerability of otlertuzumab , an anti-CD 37 mono-speci fi c ADAPTIR therapeutic protein in chronic lymphocytic leukemia
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in… 
2013
2013
Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of… 
2013
2013
Phase 1b Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIR™ Protein, In Combination With Rituximab In Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Background CD37 is a tetraspanin protein expressed on the surface of normal and transformed B-cells across a wide range of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)